A short-term retrospective analysis of the clinical, histopathological and immunohistochemical aspects of bone metastases

Monica Cîrstoiu 1 , 2 , Octavian Munteanu 1 , 2 , Tiberiu Georgescu 1 , 3 , Luciana Arsene 1 , 2 , Maria Sajin 1 , 3  and Cătălin Cîrstoiu 1 , 4
  • 1 “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • 2 Department of Obstetrics and Gynaecology, Bucharest, Romania
  • 3 Department of Pathology, Romania
  • 4 Department of Orthopaedics and Traumatology, Romania


Bone is a typical location of metastasis that usually reflects a negative outcome in oncologic patients. Once cancer has spread to the bones, it can rarely be cured, but sometimes it can be treated to minimize its rate of proliferation. Most skeletal metastases are produced by tumors originating in the breast and prostate. Osseous metastases are actually much more frequent than primary bone tumors, especially in adults. The diagnosis relies on signs, symptoms, and imaging techniques. This paper is a review of all cases of bone metastasis from our unit and a comprehensive review regarding the clinical approach and treatment of patients with such lesions.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225–249.

  • 2. Hirabayashi H, Ebara S, Kinoshita T et al. Clinical outcome and survival after palliative surgery for spinal metastases. Cancer. 2003; 97(2):476–84.

  • 3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 pt 2):6243S–6249S.

  • 4. Cooleman RE. Metastatic bone disease: Clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev. 2001; 27(3):165–1763.

  • 5. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R et al. Multidisciplinary approach to the treatment of bone metastases: Osteo-oncology center, a new organizational model. Tumori. 2009; 95:291–297.

  • 6. Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: A population-based study. Int. Urol. Nephrol. 2018; 50:71–78.

  • 7. Plunkett TA, Rubens RD. The biology and management of bone metastases. Crit. Rev. Oncol. Hematol. 1999; 31:89–96.

  • 8. Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 2004; 350:1655–1664.

  • 9. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop. Clin. N. Am. 2000; 31:515–528.

  • 10. Blum R.H., Novetsky D., Shasha D., Fleishman S. The multidisciplinary approach to bone metastases. Oncology. 2003;17:845–857; discussion 862–863, 867.

  • 11. Moriwaki S. Histopathology and statistical analysis of spinal metastases of carcinomas in autopsy cases. Orthop. Surg. Traumatol. 1993; 36:233–241.

  • 12. Vieillard MH, Thureau S. Multidisciplinary meetings dedicated to bone metastases: a historical perspective and rationale. Bull Cancer. 2013; 100:1135–9.

  • 13. Helweg-Larsen S, Henning L. Clinical and autopsy findings in spinal cord compression due to metastatic disease. European Journal of Neurology. 1998; 5.6:587-59213.

  • 14. Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Therapeutics and Clinical Risk Management. 2015; 11:1779.

  • 15. Hedayatollah H et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016; 540.7634:552.

  • 16. Niederhuber JE et al. Abeloff’s Clinical Oncology E-Book. 2019, Elsevier Health Sciences.

  • 17. Coleman RE, Brown J, Holen I. Bone metastases. Abeloff’s Clinical Oncology. Content Repository Only!. 2020; 809-830.

  • 18. Mundy GR. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer. 2002; 2.8:584.

  • 19. Guise TA et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research. 2006; 12.20:6213s-6216s.

  • 20. Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Gulley JL. A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget. 2018; 9:102, 37676.

  • 21. Mundy GR. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer. 2002; 2.8:584.

  • 22. Yeoh G, Barton S, Kaestner K. The International Journal of Biochemistry & Cell Biology. Preface. The International Journal of Biochemistry & Cell Biology. 2011; 43.2:172.


Journal + Issues